Levonorgestrel intrauterine ultra low-dose - Bayer HealthCare Pharmaceuticals

Drug Profile

Levonorgestrel intrauterine ultra low-dose - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 86-5028; Fleree; G04209C; Jaydess; LCS (ULD LNG); LCS - Bayer; LCS G04209B; LCS12; LCS16; Levonorgestrel contraceptive intrauterine systems - Bayer; Levonorgestrel ultra low-dose IUD; Levonorgestrel ultra low-dose IUS; LNG-IUS; LNS ultra low-dose IUD; LNS ultra low-dose IUS; Skyla; Ultra low-dose levonorgestrel intrauterine - Bayer; Ultra low-dose LNG intrauterine - Bayer

Latest Information Update: 28 Nov 2015

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Contraception

Most Recent Events

  • 20 Nov 2015 Adverse events data from a phase III trial in Contraception released by Bayer
  • 01 May 2015 Bayer completes a phase III trial in Contraception (In adolescents) in Austria, Belgium, Denmark, Finland, Germany, Netherlands, Sweden and Norway (NCT01434160)
  • 19 Apr 2015 Levonorgestrel intrauterine ultra low-dose (13.5mg) is still in a phase III trial for Contraception (in adolescents) in Austria, Belgium, Denmark, Finland, Germany, Netherlands, Sweden and Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top